Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

lifesciences-ip-us-ep-data-exclusivity-same-name-different-games

Join experts from Goodwin Procter and Kilburn & Strode to explore data exclusivity in the US and EP, its evolution, and strategies for life sciences.

US & EP Data Exclusivity: Same Name, Different Games

Summary

Speakers

Olivia D. Uitto

Related Content

Bio-Thera and Gedeon Richter Reach Exclusive Commercialization Agreement for Ustekinumab Biosimilar

NYDFS Publishes Guidance on AI-Related Cybersecurity Risks

Accord Biopharma Announces FDA Approval of IMULDOSA (ustekinumab-srlf)

Federal Circuit Denies Injunction Pending Appeal After Amgen Beat Preliminary Injunction for Biosimilar Aflibercept

GlaxoSmithKline and Northwestern Sue Moderna for Patent Infringement in Trio of Lawsuits

Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA

Teva and mAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership

Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab

Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction

Goodwin Advises Septerna in $288 Million Upsized Initial Public Offering

Eight Goodwin Partners Named 2025 IAM Global Leaders

Goodwin Advises TELA on $46 Million Underwritten Public Offering of Common Stock

Myricx Raises £90 Million Series A

Joshua Zachariah Named a Law360 MVP in Mergers & Acquisitions

Goodwin UK Highly Ranked in Chambers UK 2025

Goodwin Once Again Number One for M&A

Life Sciences

Intellectual Property

Patent Prosecution & Counseling